oral glp 1 agonist for type 2 diabetes GLP-1 Receptor Agonists as Treatments Choosing injectable drugs for patients

However, the dual GIP receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy in reducing HbA 1c and body weight in people with type 2 diabetes [5]

However, conflicting findings and gaps in understanding persist, calling for further research into the mechanisms underlying the influence of DPP-4 on bone metabolism

Department Physician Assistant Studies Degree Name Master of Physician Assistant Studies (MPAS) Date of Work 2025 Publication Date Spring 5-2025 Disciplines Medicine and Health Sciences Recommended Citation Fischer, Ellie, "Efficacy of GLP-1 Receptor Agonists in Obese Women with PCOS" (2025)

11 Place in Therapy In the ADA's 2018 Standards of Medical Care in Diabetes , DPP-4 inhibitors are indicated as an add-on option for patients without clinical atherosclerotic CV disease (ASCVD) who are unable to reach goal A1C after taking metformin for 3 months

Treating these conditions poses a high economic burden

The most relevant clinical data comes from Pendulum Glucose Control product (a related five-strain formulation), which demonstrated modest improvements in A1C and postprandial glucose in a small proof-of-concept trial with 76 type 2 diabetes patients